-
1.发明公开COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES 失效具有抗高血压，心脏防护，抗缺血和抗生育性质的化合物
公开(公告)号：EP0912520A1
公开(公告)日：1999-05-06
申请号：EP97933212.0
申请日：1997-07-01
发明人： MYERS, Michael, R. , MAGUIRE, Martin, P. , SPADA, Alfred, P. , EWING, William, R. , PAULS, Henry, W. , CHOI-SLEDESKI, Yong-Mi
CPC分类号： C07D401/04 , C07D473/34 , C07H19/16
摘要： This invention relates to adenosine derivatives and analogues which possess biological activity and are useful as anti-hypertensive, cardioprotective, anti-ischemic, and antilipolytic agents, to pharmaceutical compositions including such compounds, and to their use in treating hypertension, myocardial ischemia, ameliorating ischemic injury and myocardial infarct size consequent to myocardial ischemia, and treating hyperlipidemia and hypercholesterolemia, and to methods and intermediates used in the preparation of such compounds.
摘要翻译： 本发明涉及具有生物学活性并可用作抗高血压，心脏保护，抗缺血和抗脂解活性剂的腺苷衍生物和类似物，涉及包含此类化合物的药物组合物，及其在治疗高血压，心肌缺血，改善局部缺血 心肌缺血引起的心脏损伤和心肌梗塞面积，以及治疗高脂血症和高胆固醇血症，以及用于制备这些化合物的方法和中间体。
-
2.发明公开QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?1ck TYROSINE KINASES 失效喹喔啉衍生物血小板衍生生长因子和/或P56酪氨酸激酶抑制其DEN
公开(公告)号：EP1001946A1
公开(公告)日：2000-05-24
申请号：EP98926129.2
申请日：1998-05-28
发明人： SPADA, Alfred, P. , HE, Wei , MYERS, Michael, R.
IPC分类号： C07D241/44 , C07D405/10 , C07D215/20 , C07D215/38 , A61K31/47 , A61K31/495
CPC分类号： C07D215/38 , C07D215/20 , C07D241/42 , C07D241/44 , C07D241/52 , C07D241/54 , C07D403/04 , C07D405/12 , C07D453/06
摘要： This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56 tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
-
3.发明公开ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS WHICH INHIBIT CSF-1R RECEPTOR TYROSINE KINASE 失效芳基和CSF-1R的HETEROARYLCHINAZOLINVERBINDUNGEN酪氨酸激酶受体INHIBIT
公开(公告)号：EP0871448A1
公开(公告)日：1998-10-21
申请号：EP95904308.0
申请日：1994-12-08
发明人： MYERS, Michael, R. , SPADA, Alfred, P. , MAGUIRE, Martin, P. , PERSONS, Paul, E. , ZILBERSTEIN, Asher , HSU, Chin-Yi, Jenny , JOHNSON, Susan, E.
IPC分类号： A61K31 , A61P19 , A61P35 , A61P37 , A61P39 , C07C43 , C07D213 , C07D215 , C07D239 , C07D241 , C07D265 , C07D277 , C07D401 , C07D403 , C07D405 , C07D409 , C07D471
CPC分类号： C07D213/30 , A61K31/517 , A61K31/5377 , C07C43/2055 , C07C43/225 , C07C43/23 , C07D213/64 , C07D215/14 , C07D215/18 , C07D215/20 , C07D215/233 , C07D215/50 , C07D239/74 , C07D239/88 , C07D239/91 , C07D239/93 , C07D239/94 , C07D241/42 , C07D241/52 , C07D265/22 , C07D277/64 , C07D401/04 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D471/04
摘要： This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTK) inhibitors. The method of treating cell proliferation and/or differentiation or mediator release using said quinazoline compounds and their use in pharmaceutical compositions is described.
-
4.发明公开QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?lck TYROSINE KINASES 失效喹啉和血小板源性系数和/或P56 LCK酪氨酸激酶抑制喹喔啉的DEN
公开(公告)号：EP1001945A1
公开(公告)日：2000-05-24
申请号：EP98925041.0
申请日：1998-05-28
IPC分类号： C07D241/44 , C07D405/10 , C07D215/20 , C07D215/38 , A61K31/47 , A61K31/495
CPC分类号： C07D215/38 , C07D215/20 , C07D241/42 , C07D241/44 , C07D241/52 , C07D241/54 , C07D403/04 , C07D405/12 , C07D453/06
摘要： This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56 tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.
-
5.发明公开PROTEIN TYROSINE KINASE ARYL AND HETEROARYL QUINAZOLINE COMPOUNDS HAVING SELECTIVE INHIBITION OF HER-2 AUTOPHOSPHORYLATION PROPERTIES 失效具有选择性抑制HER-2自磷酸化特性的蛋白质酪氨酸激酶芳香化酶和杂芳基喹唑啉化合物
公开(公告)号：EP0831831A1
公开(公告)日：1998-04-01
申请号：EP96918362.0
申请日：1996-06-06
IPC分类号： C07D239 , A61K31 , A61P9 , A61P29 , A61P31 , A61P35 , A61P43 , C07C43 , C07D213 , C07D215 , C07D241 , C07D265 , C07D277 , C07D401 , C07D403 , C07D405 , C07D409 , C07D471
CPC分类号： C07C43/2055 , A61K31/517 , A61K31/5377 , C07C43/225 , C07C43/23 , C07D213/30 , C07D213/64 , C07D215/14 , C07D215/18 , C07D215/20 , C07D215/233 , C07D215/50 , C07D239/74 , C07D239/88 , C07D239/91 , C07D239/93 , C07D239/94 , C07D241/42 , C07D241/52 , C07D265/22 , C07D277/64 , C07D401/04 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D409/04 , C07D471/04
摘要： This invention relates to a method for the selective treatment of cell growth and differentiation characterized by activity of the human epidermal growth factor receptor type 2 (HER2). More specifically, this invention relates to the use of substituted or unsubstituted mono- or bi-cyclic aryl, heteroaryl, cycloalkyl or heterocycloalkyl compounds in selectively regulating cell growth. Pharmaceutical compositions useful for the selective treatment of cell growth and differentiation are also described.
摘要翻译： 本发明涉及以人表皮生长因子受体2型（HER2）的活性为特征的选择性治疗细胞生长和分化的方法。 更具体地说，本发明涉及取代或未取代的单环或双环芳基，杂芳基，环烷基或杂环烷基化合物在选择性调节细胞生长中的用途。 还描述了用于选择性处理细胞生长和分化的药物组合物。
-
6.发明公开PYRAZOLO 3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE 失效吡唑并（3,4-G）喹喔啉ALS PDGF受体蛋白酪氨酸激酶抑制剂
公开(公告)号：EP0779889A1
公开(公告)日：1997-06-25
申请号：EP95932446.0
申请日：1995-09-06
CPC分类号： C07D487/04
摘要： This invention relates to pyrazolo[3,4-g]quinoxaline compounds exhibiting protein tyrosine kinase inhibition activity. More specifically, compounds of this invention are novel as selective inhibitors of the PDGF-R protein tyrosine kinase and can be applied as potential therapeutic agents for various disease states which are characterized by uncontrolled cellular proliferation. Further, the present invention provides pharmaceutical compositions and a method for treating such disorders comprising the administration to a patient of a PDGF receptor inhibiting effective amount of a pyrazolo[3,4-g]quinoxaline compound exhibiting protein tyrosine kinase inhibition activity. Processes for the preparation of pyrazolo[3,4-g]quinoxaline compounds.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.013 秒)
